Latest News and Press Releases

Exton, PA, June 17, 2026 (GLOBE NEWSWIRE) -- Despite the introduction of new therapies, connective tissue disease-associated interstitial lung disease (CTD-ILD) remains an area of significant unmet...

Dr. Krish Bhadra joins medical robotics company Noah Medical as Chief Pulmonary Advisor.

With AI tools demonstrating 85–95% accuracy in biomarker identification and attracting more than $3 billion in recent funding.

According to BCC Research, the market is expected to grow from $30.2 billion in 2024 to $49.5 billion by 2030 at a CAGR of 8.8%.

24 abstracts, including 1 oral presentation and 4 late-breaking posters on Dupixent, to showcase new clinical and real-world analyses in chronic obstructive pulmonary disease (COPD) and asthma COPD...

Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils Approval marks the first new treatment approach for...

Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype Following...

Wilmington, Delaware, United States, Transparency Market Research Inc. -, Sept. 23, 2024 (GLOBE NEWSWIRE) -- According to a report published by Transparency Market Research, the global nuclear...

Noah Medical to share field results, deliver interactive simulations and host multiple events for its Galaxy System at AABIP 2024

First-in-world approval of Dupixent for adults with uncontrolled COPD with raised blood eosinophils based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations, improved...